Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | TK1 | P04183 | 1/20 | 0.37 |
| ▸ | ASAH1 | Q13510 | 2/20 | 0.36 |
| ▸ | SQOR | Q9Y6N5 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20870270 | 1.00 | CYP2C19 (0.46) | CYP2C19ALDH1A1SMN1; SMN2CYP1A2GAA | |
| SCHEMBL21275595 | 0.81 | CYP2C19 (0.51) | CYP2C19ALDH1A1SMN1; SMN2CYP1A2GAA | |
| SCHEMBL22106705 | 0.79 | CYP2C19 (0.51) | CYP2C19ALDH1A1SMN1; SMN2CYP1A2GAA | |
| SCHEMBL20334744 | 0.79 | CYP2C19 (0.51) | CYP2C19ALDH1A1SMN1; SMN2CYP1A2GAA | |
| SCHEMBL20334523 | 0.79 | CYP2C19 (0.51) | CYP2C19ALDH1A1SMN1; SMN2CYP1A2GAA | |
| SCHEMBL23353346 | 0.79 | CYP2C19 (0.51) | CYP2C19ALDH1A1SMN1; SMN2CYP1A2GAA | |
| SCHEMBL23225516 | 0.78 | SQOR (0.53) | CYP2C19ALDH1A1SMN1; SMN2CYP1A2GAA | |
| SCHEMBL20820202 | 0.78 | SMN1; SMN2 (0.59) | CYP2C19ALDH1A1SMN1; SMN2CYP1A2GAA | |
| SCHEMBL20870266 | 0.77 | SMN1; SMN2 (0.38) | CYP2C19ALDH1A1SMN1; SMN2CYP1A2TK1 | |
| SCHEMBL20870852 | 0.76 | CYP2C19 (0.48) | CYP2C19ALDH1A1SMN1; SMN2CYP1A2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11377656-B2 | Chemically modified messenger RNA's | NOVARTIS AG (CH) | 2022-07-05 | — | — | US | disclosed |
| US-20190100752-A1 | CHEMICALLY MODIFIED MESSENGER RNA'S | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2019-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190100752-A1 | CHEMICALLY MODIFIED MESSENGER RNA'S | NSUN3, RNMT, NSUN2 | CYP2C19 4873/4885ALDH1A1 3263/4885SMN1; SMN2 479/4885 |
| US-11377656-B2 | Chemically modified messenger RNA's | NSUN3, RNMT, NSUN2 | CYP2C19 4873/4885ALDH1A1 3263/4885SMN1; SMN2 479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.